arrow
A

Ann McCoy

national institutes of health (nih) - usa
H指数:7
被引数:200

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation

一项关于抗PD-L1药物Durvalumab和PARP抑制剂Olaparib在携带或不携带胚系BRCA突变的转移性三阴性乳腺癌患者中的II期探索性研究

2025-12-080
OAAI
BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor-resistant BRCAmutant ovarian cancer
2023-06-2112
OA
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors (vol 42, 76, 2023)
2023-04-262
OAAI
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
2023-03-297
OAAI